Non-Hodgkin Lymphoma (NHL) Treatment Market By Treatment Type (Chemotherapy, Immunotherapy), By Non-Hodgkins Lymphoma Type (B-cell Lymphoma, T-cell Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Non-Hodgkin Lymphoma Treatment Market size was valued at USD 478.90  and is poised to grow at a significant CAGR of 7.25% from 2023-2029. Non-Hodgkin lymphoma is caused by a combination of factors including age, gender, exposure to chemicals such as benzene and pesticides, a compromised immune system, and chemical exposure. Over the forecast period, increased awareness of cancer diagnosis and treatment, as well as government intervention with various cost-effective policies, are likely to enhance the Non-Hodgkins Lymphoma (NHL) market. Despite the fact that numerous medications are available for NHL, none of them are effective at the end stage, which may limit the growth of the non-hodgkin lymphoma treatment market throughout the projection period. Non-Hodgkins Lymphoma (NHL) is a kind of cancer caused by aberrant B or T lymphocyte and leukocyte function. These lymphomas typically develop in the bone marrow, lymph nodes, spleen, blood, and other lymphatic organs. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Non-Hodgkin Lymphoma Treatment Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

Non Hodgkin Lymphoma Nhl Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

7.25%

Largest Market

North-America

Fastest Growing Market

Europe
Non-Hodgkin Lymphoma Treatment Market Dynamics

The market is driven by factors such as demand for innovative drugs and novel technologies, FDA approval of chronic lymphocytic leukaemia therapy drugs, introduction of promising drugs such as novel small molecule inhibitors and next-generation monoclonal antibodies, and an increase in the prevalence of NHL. The expensive expense of vaccinations used in NHL therapy, as well as the negative effects associated with them, limit market expansion.

Non Hodgkin Lymphoma Nhl Treatment Market Segmentation

By Treatment Type
  • Chemotherapy
  • Immunotherapy
By Non-Hodgkins Lymphoma Type
  • B-cell Lymphoma
  • T-cell Lymphoma
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Frequently Asked Questions

2022 is the base year and 2029 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Europe is the fastest-growing for Non-Hodgkin Lymphoma Treatment Market

Non-Hodgkin Lymphoma Treatment Market is poised to grow at a significant CAGR of 7.25%

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
1.Executive Summary
2.Global Non-Hodgkin Lymphoma Treatment Market Introduction 
2.1.Global Non-Hodgkin Lymphoma Treatment Market  - Taxonomy
2.2.Global Non-Hodgkin Lymphoma Treatment Market  - Definitions
2.2.1.Treatment Type
2.2.2.Non-Hodgkins Lymphoma Type
2.2.3.Distribution Channel
2.2.4.Region
3.Global Non-Hodgkin Lymphoma Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Non-Hodgkin Lymphoma Treatment Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Non-Hodgkin Lymphoma Treatment Market  By Treatment Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Chemotherapy
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Immunotherapy
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Non-Hodgkin Lymphoma Treatment Market  By Non-Hodgkins Lymphoma Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. B-cell Lymphoma
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. T-cell Lymphoma
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Non-Hodgkin Lymphoma Treatment Market  By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Non-Hodgkin Lymphoma Treatment Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Non-Hodgkin Lymphoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Treatment Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Chemotherapy
9.1.2.Immunotherapy
9.2.  Non-Hodgkins Lymphoma Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.B-cell Lymphoma
9.2.2.T-cell Lymphoma
9.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Others
9.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Non-Hodgkin Lymphoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Chemotherapy
10.1.2.Immunotherapy
10.2.  Non-Hodgkins Lymphoma Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.B-cell Lymphoma
10.2.2.T-cell Lymphoma
10.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Others
10.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11.Asia Pacific (APAC) Non-Hodgkin Lymphoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Chemotherapy
11.1.2.Immunotherapy
11.2.  Non-Hodgkins Lymphoma Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.B-cell Lymphoma
11.2.2.T-cell Lymphoma
11.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Others
11.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Non-Hodgkin Lymphoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Chemotherapy
12.1.2.Immunotherapy
12.2.  Non-Hodgkins Lymphoma Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.B-cell Lymphoma
12.2.2.T-cell Lymphoma
12.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Others
12.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Non-Hodgkin Lymphoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Chemotherapy
13.1.2.Immunotherapy
13.2.  Non-Hodgkins Lymphoma Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.B-cell Lymphoma
13.2.2.T-cell Lymphoma
13.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Others
13.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.F. Hoffmann-La Roche AG
14.2.2.Seattle Genetics
14.2.3.Spectrum Pharmaceuticals
14.2.4.Celgene
14.2.5.Millennium/Johnson-Johnson
14.2.6.Merck Inc.
14.2.7.Pharmacyclics/Janssen Biotech
14.2.8.Kyowa Hakko Kirin
14.2.9.CTI Biopharma
15. Research Methodology 
16. Appendix and Abbreviations 
  • F. Hoffmann-La Roche AG
  • Seattle Genetics
  • Spectrum Pharmaceuticals
  • Celgene
  • Millennium/Johnson-Johnson
  • Merck Inc.
  • Pharmacyclics/Janssen Biotech
  • Kyowa Hakko Kirin
  • CTI Biopharma

Adjacent Markets